Mereo BioPharma Group shares are trading higher after the company announced an optional and license agreement with Zydus Unit Sentynl For U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.

Benzinga Newsdesk www.benzinga.com Positive 95.1%

Neg 0% Neu 0% Pos 95.1%

Comments

No comments yet. Be the first!